Lactation protein suppresses tumors and metastasis in breast cancer, scientists discover

October 24, 2012

A protein that is necessary for lactation in mammals inhibits the critical cellular transition that is an early indicator of breast cancer and metastasis, according to research conducted at the University at Buffalo and Princeton University and highlighted as the cover paper in November issue of Nature Cell Biology.

"This is the first confirmed report that this protein, called Elf5, is a in breast cancer," explains Satrajit Sinha, PhD, associate professor of biochemistry in the UB School of Medicine and Biomedical Sciences and a corresponding author on the paper with Yibin Kang, PhD, in the Department of Molecular Biology at Princeton University.

The researchers say the findings provide new avenues to pursue in treating and diagnosing breast cancer and possibly cancers of other organs as well. The paper includes findings from both animal and human breast cancer models.

Under normal circumstances, Elf5 is a transcription factor that controls the genes that allow for milk production.

But when the researchers used developed at UB, in whom Elf5 was removed, they found more than just an inability to produce milk. They found that epithelial cells in the also became more mesenchymal, that is, more like stem cells, an early harbinger of cancer, Sinha says.

"We found that when Elf5 levels are low or absent, epithelial cells become more like stem cells, morphing into , changing their shape and appearance and migrating elsewhere in the body," says Sinha. "This is how cancer spreads."

The UB-Princeton collaboration began when lead author Rumela Chakrabarti, PhD, originally a postdoctoral researcher in Sinha's laboratory at UB, took a position in the laboratory of Yibin Kang, PhD, Warner-Lambert/Parke-Davis Professor of at Princeton, whose research focus is . This allowed Chakrabarti to harness the expertise of the two laboratories to generate such a breakthrough finding.

"Elf5 keeps normal breast cells in their current shape and restricts their movement," says Chakrabarti. She found that the protein accomplishes this by suppressing the epithelial-mesenchymal transition by directly repressing transcription of Snail2, a master regulator of mammary known to trigger the EMT.

"Elf5 keeps Snail2 repressed, but once Elf5 is lost, then there is nothing to repress Snail 2," she explains.

The paper notes that Elf5 loss is frequently detected early in the disease at the breast hyperplasia stage, when the number of cells increases. In experiments conducted by the Princeton scientists, the researchers also found that little or no Elf5 in human breast cancer samples correlated with increased morbidity.

"It seems that loss of Elf5 is an initial event in the disease, so it could also be an important diagnostic tool," Sinha notes, which is a current focus of the UB and Princeton team.

"We want to know, how early does the loss of Elf5 occur? Could we use loss of Elf5 as a reliable diagnostic tool?" he asks.

The finding reveals the complex pathways through which breast cancers develop, he says, while also providing new avenues to pursue for diagnostics and treatments.

"Our research shows that the EMT-Snail 2 pathway is a valuable one to target for early intervention," says Sinha, "possibly by designing something to recapture the repressive effect of Elf5 or a drug that could mimic Elf5 activity. And this is just one molecule, part of a big network. That's why we are now creating a detailed map of this molecule and its associated partners in order to give us a better idea of what to look for."

Explore further: New study shows promise for developing new treatments for breast cancer

Related Stories

New study shows promise for developing new treatments for breast cancer

March 14, 2012
A new study by University of Kentucky researchers provides insight into developing new treatment strategies for basal-like breast cancer, commonly known as triple-negative breast cancer. This cancer is associated with early ...

Cellular 'glue' resists breast cancer

April 20, 2012
Early detection and advances in the treatment for breast cancer have improved the chances of survival, however new avenues for treatment are still needed in the battle against this disease. New research published in BioMed ...

Signaling pathways point to vulnerability in breast cancer stem cells

June 9, 2011
Whitehead Institute researchers have identified signals from breast epithelial cells that can induce those cells to transition to and maintain a mesenchymal and stem cell-like cell state that imbues both normal and cancer ...

RANK protein promotes the initiation, progression and metastasis of human breast cancer

April 24, 2012
Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) have shown that overactivation of the RANK signalling pathway promotes the initiation, progression and metastasis of tumours in human breast epithelial ...

Recommended for you

Researchers develop test that can diagnose two cancer types

December 12, 2017
A blood test using infrared spectroscopy can be used to diagnose two types of cancer, lymphoma and melanoma, according to a study led by Georgia State University.

Atoh1, a potential Achilles' heel of Sonic Hedgehog medulloblastoma

December 12, 2017
Medulloblastoma is the most common type of solid brain tumor in children. Current treatments offer limited success and may leave patients with severe neurological side effects, including psychiatric disorders, growth retardation ...

Cancer-causing mutation suppresses immune system around tumours

December 12, 2017
Mutations in 'Ras' genes, which drive 25% of human cancers by causing tumour cells to grow, multiply and spread, can also protect cancer cells from the immune system, finds a new study from the Francis Crick Institute and ...

Drug suppresses spread of breast cancer caused by stem-like cells

December 12, 2017
Rare stem-like tumor cells play a critical role in the spread of breast cancer, but a vulnerability in the pathway that powers them offers a strategy to target these cells using existing drugs before metastatic disease occurs, ...

MRI scans predict patients' ability to fight the spread of cancer

December 12, 2017
A simple, non-invasive procedure that can indicate how long patients with cancer that has spread to the brain might survive and whether they are likely to respond to immunotherapy has been developed by researchers in Liverpool.

Scientists discover possible master switch for programming cancer immunotherapy

December 11, 2017
During infection or tumor growth, a type of specialized white blood cells called CD8+ T cells rapidly multiply within the spleen and lymph nodes and acquire the ability to kill diseased cells. Some of these killer T cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.